Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy recommendation. Analyst Price Forecast Suggests 7.55% Upside As of January ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Shares of Axsome Therapeutics ( AXSM 4.07%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

Axsome Therapeutics (AXSM – Research Report ... The potential regulatory approvals for AXS-07, AXS-14, and AXS-12 in the near to medium term, along with the expected submission of AXS-05 ...

Axsome Therapeutics’ AXSM shares have rallied ... s portfolio of pipeline candidates includes AXS-07, AXS-12 and AXS-14, all of which are being developed for various CNS indications.

Ratings for Axsome Therapeutics AXSM were provided ... Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...

Axsome's lead candidate ... Some analysts project that AXS-05 could generate over $500 million in AD agitation revenue five years post-launch, with a 14% peak penetration rate.

Axsome Therapeutics ... Analysts project that AXS-05 could generate over $500 million in AD agitation revenue five years post-launch, with a 14% peak penetration rate. The company is also ...

Axsome Therapeutics’ AXSM shares have rallied ... Axsome’s commercial portfolio includes Auvelity (AXS-05) which was launched in the United States in 2022 to treat major depressive disorder.

Axsome's lead candidate, AXS-05, is currently in late-stage development for the treatment of Alzheimer's Disease Agitation (ADA). This condition affects approximately 70% of Alzheimer's patients and ...